Welcome to our dedicated page for CytoMed Therapeutics news (Ticker: GDTC), a resource for investors and traders seeking the latest updates and insights on CytoMed Therapeutics stock.
CytoMed Therapeutics Limited reports developments in cell-based immunotherapies for cancer as a Singapore-based clinical-stage biopharmaceutical company. Its updates center on donor-derived allogeneic programs, including CAR γδ T cell therapies, iPSC-derived γδ NKT cell therapies, and γδ T cell product candidates such as CTM-N2D and CTM-GDT for blood and solid tumors.
Recurring news also covers clinical and regulatory disclosures, preclinical research publications, hospital and research collaborations, and the expansion of cord blood-derived Natural Killer cell work through LongevityBank and its licensed cord blood bank assets in Malaysia. Company communications include subsidiary investments, international expansion initiatives, shareholder ownership updates, and responses to public claims about its programs and operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CytoMed Therapeutics Limited (Nasdaq: GDTC) has successfully completed its initial public offering (IPO), raising a total of US$9,649,476 through the sale of 2,412,369 ordinary shares priced at US$4.00 each. The IPO marks a significant step for the pre-clinical biopharmaceutical company, which specializes in developing innovative cell-based immunotherapies for cancer treatment. Shares started trading on the Nasdaq Capital Market on April 14, 2023. Underwriters also have a 45-day option to purchase an additional 361,855 shares. The offering was facilitated by The Benchmark Company, LLC and Axiom Capital Management, Inc. Regulatory approvals were secured with the SEC declaring the corresponding registration effective on March 31, 2023.
CytoMed Therapeutics Limited has announced the pricing of its initial public offering (IPO) at US$4.00 per share, aiming to raise US$9.65 million in gross proceeds. The IPO includes 2,412,369 ordinary shares, with an option for underwriters to purchase an additional 361,855 shares for over-allotments. Trading on the Nasdaq Capital Market under the ticker symbol GDTC is set to begin on April 14, 2023, with the offering expected to close on April 18, 2023. Proceeds will support the clinical development of multiple product candidates and R&D activities. The offering follows SEC approval of the registration statement on March 31, 2023.